{ "dataset_id": "CP-WEB-EVIDENCE-MAP-01", "version": "2026-10-15", "description_en": "Curated, paraphrased source-to-claim metadata for the community-practice library. No participant records or clinical outcome dataset. Editorial and scientific review status remains visible.", "description_es": "Metadatos curados y parafraseados de fuentes y afirmaciones. Sin registros de participantes ni base de resultados clínicos. Se conserva el estado editorial y científico.", "sources": { "V1": { "id": "V1", "title": "Péptidos en la práctica — Volumen 1 (supplied edition; publication metadata not established)", "pdf_page_count": 68 }, "V2": { "id": "V2", "title": "Péptidos en la práctica — Volumen 2 (supplied edition; publication metadata not established)", "pdf_page_count": 64 }, "V3": { "id": "V3", "title": "Péptidos en la práctica — Volumen 3 (supplied edition; publication metadata not established)", "pdf_page_count": 31 }, "V4": { "id": "V4", "title": "Péptidos en la práctica — Volumen 4 (supplied edition; publication metadata not established)", "pdf_page_count": 71 }, "V5": { "id": "V5", "title": "Péptidos en la práctica — Volumen 5 (supplied edition; publication metadata not established)", "pdf_page_count": 28 }, "BONO2": { "id": "BONO2", "title": "BONO2 — Comprador inteligente / buyer-quality guide (supplied edition)", "pdf_page_count": 6 }, "H": { "id": "H", "title": "LaValle, Crozier, Cleaver and Heyman — Peptide Handbook (copyright 2022; supplied copy)", "pdf_page_count": 281 }, "S": { "id": "S", "title": "William A. Seeds — The Peptide Protocols, Volume 1 (2020; supplied copy)", "pdf_page_count": 272 } }, "profiles": [ { "id": "CP-bpc-157", "slug": "bpc-157", "name": "BPC-157", "category": "recovery", "claim_ids": [ "C005", "C006", "C007" ], "source_locators": "V2 PDF13; source-to-claim matrix C005–C007", "references": [ "R01", "R07", "R08", "R09" ], "review_status": "editorial_draft_scientific_review_pending", "last_editorial_audit": "2026-10-15", "en": { "reported_practice": "Practitioner and community sources describe BPC-157 for tendon, muscle and gastrointestinal complaints, sometimes with TB-500 or other compounds. Accounts differ in route, duration and intended outcomes.", "proposed_rationale": "The proposed explanation draws on repair-related signaling and laboratory findings. A cellular mechanism can motivate a research question without establishing recovery in people.", "evidence": "Tendon experiments provide preclinical findings. Small uncontrolled human reports include retrospective knee-pain observations and a two-person intravenous pilot; these are different interventions and endpoints.", "limits": "Pain improvement does not demonstrate regenerated cartilage or tendon healing. Short observation of two people cannot establish uncommon or delayed harms, and ingredient reports do not establish stack superiority.", "product_question": "What molecule, route, formulation and lot were actually used? A label alone cannot connect a commercial vial to a study intervention.", "research_question": "Can independently chosen exposures be documented alongside comparable pain/function outcomes, rehabilitation, training changes and follow-up completeness?" }, "es": { "reported_practice": "Fuentes profesionales y comunitarias describen BPC-157 para molestias tendinosas, musculares y gastrointestinales, a veces junto con TB-500 u otros compuestos. Los relatos difieren en vía, duración y desenlace buscado.", "proposed_rationale": "La explicación propuesta se apoya en señalización relacionada con reparación y hallazgos de laboratorio. Un mecanismo celular permite formular preguntas sin demostrar recuperación en personas.", "evidence": "Los experimentos de tendón aportan evidencia preclínica. Hay informes humanos pequeños sin control: observaciones retrospectivas de dolor de rodilla y un piloto intravenoso de dos personas, con intervenciones y desenlaces diferentes.", "limits": "Menos dolor no demuestra regeneración de cartílago ni reparación tendinosa. La observación breve de dos personas no establece daños infrecuentes o tardíos; los informes de componentes no prueban superioridad de una mezcla.", "product_question": "¿Qué molécula, vía, formulación y lote se utilizaron? La etiqueta no conecta por sí sola un vial comercial con la intervención de un estudio.", "research_question": "¿Pueden documentarse exposiciones elegidas independientemente junto con dolor, función, rehabilitación, entrenamiento y seguimiento comparable?" }, "pdf_claim_links": [ { "claim_id": "C005", "source_id": "V2", "pdf_pages": "3–10; especially 8" }, { "claim_id": "C006", "source_id": "V2", "pdf_pages": "6, 10, 13; 13" }, { "claim_id": "C007", "source_id": "V2", "pdf_pages": "11–13" } ] }, { "id": "CP-cjc-1295", "slug": "cjc-1295", "name": "CJC-1295 / “without DAC”", "category": "gh-axis", "claim_ids": [ "C009", "C010" ], "source_locators": "V2 CJC discussion; matrix C009–C010", "references": [ "R10", "R11" ], "review_status": "editorial_draft_scientific_review_pending", "last_editorial_audit": "2026-10-15", "en": { "reported_practice": "Sources describe CJC products, often paired with ipamorelin, for sleep, body composition and recovery. “Without DAC” is a naming issue that must be resolved rather than treated as a minor variation.", "proposed_rationale": "The rationale combines growth-hormone-releasing signaling with another secretagogue. Proposed complementary actions do not demonstrate additional functional benefit.", "evidence": "Human long-acting CJC-1295 studies measured hormone exposure. A human pulsatility study does not support the simple claim that DAC abolishes GH pulses.", "limits": "Those studies do not validate every product marketed as CJC without DAC or a nightly community combination. Higher GH/IGF-1 is not itself better sleep or injury recovery.", "product_question": "Is this the long-acting studied molecule, Mod GRF, or an incompletely identified commercial product? Retain the precise identity.", "research_question": "How much naming ambiguity exists in documented exposures, and how often do reports include the exact formulation rather than only “CJC”?" }, "es": { "reported_practice": "Las fuentes describen productos CJC, frecuentemente combinados con ipamorelina, para sueño, composición corporal y recuperación. “Sin DAC” exige aclarar identidad, no asumir una variación menor.", "proposed_rationale": "La lógica combina señalización liberadora de hormona de crecimiento con otro secretagogo. La complementariedad propuesta no demuestra beneficio funcional adicional.", "evidence": "Estudios humanos de CJC-1295 de acción prolongada midieron exposición hormonal. Un estudio de pulsatilidad no respalda la afirmación simple de que DAC elimina los pulsos de GH.", "limits": "Esos estudios no validan todos los productos llamados CJC sin DAC ni una combinación comunitaria nocturna. Más GH/IGF-1 no equivale por sí mismo a mejor sueño o recuperación.", "product_question": "¿Es la molécula de acción prolongada estudiada, Mod GRF o un producto comercial de identidad incompleta? Conserva la identidad precisa.", "research_question": "¿Cuánta ambigüedad de nombres existe en las exposiciones documentadas y cuántos relatos especifican la formulación?" }, "pdf_claim_links": [ { "claim_id": "C009", "source_id": "V2", "pdf_pages": "14–19" }, { "claim_id": "C010", "source_id": "V2", "pdf_pages": "15" } ] }, { "id": "CP-ipamorelin", "slug": "ipamorelin", "name": "Ipamorelin / Ipamorelina", "category": "gh-axis", "claim_ids": [ "C009", "C077" ], "source_locators": "Seeds PDF97–99; matrix critical-unit-error record", "references": [ "R12", "R06" ], "review_status": "editorial_draft_scientific_review_pending", "last_editorial_audit": "2026-10-15", "en": { "reported_practice": "Ipamorelin appears in community GH-secretagogue combinations. Some sources present cycling and timing as established principles without direct comparisons.", "proposed_rationale": "The proposed rationale is stimulation of GH release. A hormonal response and a meaningful clinical outcome are separate questions.", "evidence": "A controlled postoperative intravenous study did not demonstrate significance for its key meal-tolerance endpoint. Its population, route and purpose differ from community recovery use.", "limits": "A negative result in that indication does not prove universal inactivity. It also does not validate subcutaneous performance stacks. One source contains an apparent dose-unit error that must not be silently corrected.", "product_question": "Identify formulation and route, and check the source document for an erratum before reusing any ambiguous number.", "research_question": "What proportion of recorded community claims can be traced to a study with the same intervention and outcome?" }, "es": { "reported_practice": "La ipamorelina aparece en combinaciones comunitarias de secretagogos de GH. Algunas fuentes presentan ciclos y horarios como principios establecidos sin comparaciones directas.", "proposed_rationale": "La lógica propuesta es estimular liberación de GH. La respuesta hormonal y un resultado clínico relevante son preguntas diferentes.", "evidence": "Un estudio controlado intravenoso posoperatorio no mostró significación en su desenlace clave de tolerancia alimentaria. Población, vía y objetivo difieren del uso comunitario para recuperación.", "limits": "Un resultado negativo en esa indicación no demuestra inactividad universal ni valida combinaciones subcutáneas de rendimiento. Una fuente contiene un aparente error de unidad que no debe corregirse por suposición.", "product_question": "Identifica formulación y vía; comprueba si existe una errata antes de reutilizar una cifra ambigua.", "research_question": "¿Qué proporción de afirmaciones comunitarias se conecta con estudios de la misma intervención y desenlace?" }, "pdf_claim_links": [ { "claim_id": "C009", "source_id": "V2", "pdf_pages": "14–19" }, { "claim_id": "C077", "source_id": "S", "pdf_pages": "97–99" } ] }, { "id": "CP-tb-500", "slug": "tb-500", "name": "TB-500 / thymosin β4", "category": "recovery", "claim_ids": [ "C012" ], "source_locators": "V2 TB discussion; Seeds PDF160; matrix C012 and unit-error record", "references": [ "R03", "R35" ], "review_status": "editorial_draft_scientific_review_pending", "last_editorial_audit": "2026-10-15", "en": { "reported_practice": "TB-500 is described for repair and in Wolverine-type combinations. Sources and sellers may use overlapping names for different materials.", "proposed_rationale": "Claims borrow from thymosin beta-4 biology, including cell migration and repair. Evidence transfer requires the same molecule, not a shared name.", "evidence": "The FDA scientific assessment distinguishes TB-500-related substances from full-length thymosin beta-4. A topical ocular trial of the latter does not test injected vendor TB-500.", "limits": "The ocular trial’s primary endpoints were not positive, despite some secondary findings. Neither those findings nor laboratory data establish systemic repair-stack effectiveness.", "product_question": "Which sequence and modifications were confirmed? The common name does not guarantee chemical identity, salt form or equivalence.", "research_question": "Can exposure records distinguish verified sequence, label-only identity and unknown material before outcomes are grouped?" }, "es": { "reported_practice": "TB-500 se describe para reparación y en combinaciones tipo Wolverine. Fuentes y vendedores pueden emplear nombres coincidentes para materiales diferentes.", "proposed_rationale": "Las afirmaciones recurren a la biología de timosina beta-4, incluida migración celular y reparación. Transferir evidencia exige identidad molecular, no solo un nombre compartido.", "evidence": "La evaluación científica de FDA distingue sustancias relacionadas con TB-500 de timosina beta-4 completa. Un ensayo ocular tópico de esta última no estudia TB-500 comercial inyectado.", "limits": "Los desenlaces principales del ensayo ocular no fueron positivos, aunque hubo hallazgos secundarios. Ni estos ni los datos de laboratorio establecen eficacia de combinaciones sistémicas de reparación.", "product_question": "¿Qué secuencia y modificaciones se confirmaron? El nombre común no garantiza identidad química, sal ni equivalencia.", "research_question": "¿Pueden distinguirse secuencia verificada, identidad solo declarada y material desconocido antes de agrupar resultados?" }, "pdf_claim_links": [ { "claim_id": "C012", "source_id": "V2", "pdf_pages": "20–21; V4 22" } ] }, { "id": "CP-ghk-cu", "slug": "ghk-cu", "name": "GHK-Cu", "category": "skin", "claim_ids": [ "C013" ], "source_locators": "V2 PDF22 and GHK discussion; matrix C013", "references": [ "R06" ], "review_status": "editorial_draft_scientific_review_pending", "last_editorial_audit": "2026-10-15", "en": { "reported_practice": "GHK-Cu is described for skin, hair and systemic repair and appears in Glow/KLOW mixtures. Topical and injected practices are often discussed together.", "proposed_rationale": "Copper-peptide biology and gene-expression observations are offered as a rationale. A large number of affected genes is not a clinical effect-size measure.", "evidence": "The audit found a heterogeneous evidence base and a critical route-transfer problem. Cosmetic or laboratory findings must retain their exact intervention and endpoints.", "limits": "Do not describe systemic injection as established on the strength of topical observations. The same caution applies to efficacy and safety of fixed mixtures.", "product_question": "Distinguish GHK-Cu from AHK-Cu, copper content from peptide identity, and topical finished product from injectable material.", "research_question": "How often do reported outcomes retain route, product identity, photographs with consistent conditions and other skin/hair treatments?" }, "es": { "reported_practice": "GHK-Cu se describe para piel, cabello y reparación sistémica y aparece en mezclas Glow/KLOW. Con frecuencia se discuten juntas prácticas tópicas e inyectadas.", "proposed_rationale": "La biología de péptidos de cobre y observaciones de expresión génica se ofrecen como fundamento. El número de genes afectados no mide magnitud de beneficio clínico.", "evidence": "La auditoría encontró evidencia heterogénea y un problema de extrapolación entre vías. Los hallazgos cosméticos o de laboratorio deben conservar intervención y desenlaces exactos.", "limits": "No se debe presentar la inyección sistémica como establecida por observaciones tópicas. La misma precaución aplica a eficacia y seguridad de mezclas fijas.", "product_question": "Distingue GHK-Cu de AHK-Cu, contenido de cobre de identidad peptídica y producto tópico de material inyectable.", "research_question": "¿Con qué frecuencia los relatos conservan vía, identidad, fotografías comparables y tratamientos concomitantes de piel/cabello?" }, "pdf_claim_links": [ { "claim_id": "C013", "source_id": "V2", "pdf_pages": "22–23; V4 5–8" } ] }, { "id": "CP-aod-9604", "slug": "aod-9604", "name": "AOD-9604", "category": "metabolic", "claim_ids": [ "C014", "C015" ], "source_locators": "V2 PDF53–55; Seeds PDF174–177", "references": [ "R04" ], "review_status": "editorial_draft_scientific_review_pending", "last_editorial_audit": "2026-10-15", "en": { "reported_practice": "AOD-9604 is promoted for fat loss and paired with GH-axis or metabolic products. One volume incorrectly equates an hCG-labeled fragment with AOD.", "proposed_rationale": "The proposed rationale derives from a modified growth-hormone fragment. hCG and hGH are different hormones; a similar fragment label cannot settle molecular identity.", "evidence": "The FDA review describes Tyr-hGH(177–191) and unsuccessful obesity evidence, including a large randomized study. The clinical findings should remain visible beside the mechanism.", "limits": "Food-use GRAS context does not constitute injectable drug approval. Oral-study results cannot establish the effectiveness or safety of a different injected regimen.", "product_question": "Confirm exact sequence/modifications and product formulation rather than accepting AOD and “fragment” as interchangeable.", "research_question": "Which marketed identities and claims depart from the studied molecule, and can those mismatches be quantified in an evidence map?" }, "es": { "reported_practice": "AOD-9604 se promociona para pérdida de grasa y se combina con productos metabólicos o del eje GH. Un volumen equipara incorrectamente un fragmento rotulado hCG con AOD.", "proposed_rationale": "La lógica deriva de un fragmento modificado de hormona de crecimiento. hCG y hGH son hormonas distintas; un nombre parecido no resuelve identidad.", "evidence": "La revisión FDA describe Tyr-hGH(177–191) y evidencia de obesidad sin éxito, incluido un ensayo aleatorizado grande. Los resultados clínicos deben acompañar al mecanismo.", "limits": "El contexto GRAS alimentario no constituye aprobación de un fármaco inyectable. Estudios orales no establecen eficacia o seguridad de otra pauta inyectada.", "product_question": "Confirma secuencia, modificaciones y formulación exactas; no asumas equivalencia entre AOD y “fragmento”.", "research_question": "¿Qué identidades y afirmaciones comerciales se apartan de la molécula estudiada y pueden cuantificarse esas diferencias?" }, "pdf_claim_links": [ { "claim_id": "C014", "source_id": "V2", "pdf_pages": "24–25" }, { "claim_id": "C015", "source_id": "V2", "pdf_pages": "53–55; 54–55" } ] }, { "id": "CP-tesamorelin", "slug": "tesamorelin", "name": "Tesamorelin / Tesamorelina", "category": "gh-axis", "claim_ids": [ "C025" ], "source_locators": "V2 tesamorelin discussion; matrix C025", "references": [ "R13" ], "review_status": "editorial_draft_scientific_review_pending", "last_editorial_audit": "2026-10-15", "en": { "reported_practice": "Community guides extend visceral-fat findings to short athletic or body-composition cycles and sometimes suggest special diluents.", "proposed_rationale": "Tesamorelin acts in the GH-releasing pathway. A mechanism or a narrow visceral-fat result does not establish a general weight-loss or anti-aging use.", "evidence": "An approved US product context concerns excess abdominal fat in adults with HIV-associated lipodystrophy. Product versions have specific labeling and handling instructions.", "limits": "The approved population and endpoint cannot be transferred to healthy athletic users. WR/SV presentation differences also defeat universal reconstitution and storage rules.", "product_question": "What exact authorized presentation, instructions and jurisdiction are being cited? A vendor vial does not inherit a brand label.", "research_question": "How frequently do community summaries omit the actual approved population or mix handling instructions between presentations?" }, "es": { "reported_practice": "Guías comunitarias extienden resultados sobre grasa visceral a ciclos deportivos o de composición corporal y a veces proponen diluyentes especiales.", "proposed_rationale": "La tesamorelina actúa en la vía liberadora de GH. Un mecanismo o un resultado acotado de grasa visceral no establece uso general para adelgazar o antienvejecimiento.", "evidence": "El contexto de un producto aprobado en Estados Unidos corresponde a exceso de grasa abdominal en adultos con lipodistrofia asociada a VIH. Las presentaciones tienen instrucciones específicas.", "limits": "No se transfieren población y desenlace aprobados a deportistas sanos. Las diferencias WR/SV también impiden reglas universales de conservación y reconstitución.", "product_question": "¿Qué presentación autorizada, instrucciones y jurisdicción se citan? Un vial comercial ajeno no hereda la ficha de una marca.", "research_question": "¿Con qué frecuencia los resúmenes omiten la población aprobada o mezclan instrucciones de presentaciones?" }, "pdf_claim_links": [ { "claim_id": "C025", "source_id": "V2", "pdf_pages": "39" } ] }, { "id": "CP-bremelanotide", "slug": "bremelanotide", "name": "Bremelanotide / PT-141", "category": "sexual-health", "claim_ids": [ "C032", "C067" ], "source_locators": "V2 PT-141 discussion; matrix bremelanotide record", "references": [ "R31" ], "review_status": "editorial_draft_scientific_review_pending", "last_editorial_audit": "2026-10-15", "en": { "reported_practice": "PT-141 is described for sexual desire and performance across broad populations, including uses outside the studied product indication.", "proposed_rationale": "Melanocortin signaling is offered as the explanation. Desire, arousal and performance are distinct endpoints, not a single universal response.", "evidence": "The US Vyleesi label concerns a specific form of acquired generalized low desire in premenopausal women. That is not approval for men or every sexual complaint.", "limits": "Blood-pressure effects and labeled cardiovascular restrictions are material. A positive result for the authorized product does not establish a community stack or another preparation.", "product_question": "Confirm product, indication, population and relevant label restrictions before interpreting any claim.", "research_question": "Which outcomes do reports actually describe, and do they separate desire, function, adverse effects and concomitant medicines?" }, "es": { "reported_practice": "PT-141 se describe para deseo y rendimiento sexual en poblaciones amplias, incluidos usos ajenos a la indicación estudiada.", "proposed_rationale": "La señalización melanocortínica se ofrece como explicación. Deseo, excitación y rendimiento son desenlaces distintos, no una respuesta universal.", "evidence": "La ficha estadounidense Vyleesi corresponde a una forma específica de deseo bajo adquirido y generalizado en mujeres premenopáusicas. No aprueba uso en hombres ni toda consulta sexual.", "limits": "Los efectos sobre presión arterial y restricciones cardiovasculares son relevantes. Un resultado del producto autorizado no establece una combinación ni otro preparado.", "product_question": "Confirma producto, indicación, población y restricciones pertinentes antes de interpretar la afirmación.", "research_question": "¿Qué desenlaces describen los relatos y distinguen deseo, función, efectos adversos y medicamentos concomitantes?" }, "pdf_claim_links": [ { "claim_id": "C032", "source_id": "V2", "pdf_pages": "48–50; V4 16–17" }, { "claim_id": "C067", "source_id": "H", "pdf_pages": "113–119, 193–194" } ] }, { "id": "CP-melanotan", "slug": "melanotan", "name": "Melanotan II / tanning claims", "category": "skin", "claim_ids": [ "C031" ], "source_locators": "V2 melanotan discussion; matrix UV and melanotan records", "references": [ "R32", "R33", "R34" ], "review_status": "editorial_draft_scientific_review_pending", "last_editorial_audit": "2026-10-15", "en": { "reported_practice": "Community sources describe pigmentation and tanning routines, sometimes with deliberate ultraviolet exposure. Unregulated nasal products are another route of exposure.", "proposed_rationale": "Pigmentation signaling is not equivalent to protection from ultraviolet injury. Afamelanotide and melanotan II must remain distinct.", "evidence": "An afamelanotide product has a narrow approved context. TGA testing of a small set of melanotan sprays found content inconsistent with labels.", "limits": "Do not transfer afamelanotide approval to melanotan II or interpret increased pigmentation as sunscreen protection. A targeted testing sample is not a market-wide prevalence estimate.", "product_question": "Is the substance and route actually verified, and does the label match measured content?", "research_question": "Can an evidence map identify where tanning claims substitute pigmentation for a clinically meaningful protection outcome?" }, "es": { "reported_practice": "Fuentes comunitarias describen pigmentación y rutinas de bronceado, a veces con exposición ultravioleta deliberada. Los productos nasales no regulados añaden otra vía de exposición.", "proposed_rationale": "Señalización de pigmentación no equivale a protección frente a daño ultravioleta. Afamelanotida y melanotan II deben permanecer diferenciados.", "evidence": "Un producto de afamelanotida tiene un contexto aprobado acotado. TGA halló contenido discordante con etiquetas en una muestra pequeña de aerosoles melanotan.", "limits": "No transfieras la aprobación de afamelanotida a melanotan II ni interpretes pigmentación como protección solar. Una muestra dirigida no estima prevalencia de todo el mercado.", "product_question": "¿Se verificaron sustancia y vía, y coincide la etiqueta con el contenido medido?", "research_question": "¿Puede identificarse dónde una afirmación sustituye pigmentación por un desenlace clínico de protección?" }, "pdf_claim_links": [ { "claim_id": "C031", "source_id": "V2", "pdf_pages": "48–50" } ] }, { "id": "CP-kpv", "slug": "kpv", "name": "KPV", "category": "gut-immune", "claim_ids": [ "C026", "C062" ], "source_locators": "V2 PDF40; matrix KPV records", "references": [ "R02", "R14" ], "review_status": "editorial_draft_scientific_review_pending", "last_editorial_audit": "2026-10-15", "en": { "reported_practice": "KPV appears in gut, skin and inflammation protocols, alone or with BPC-157 and LL-37. Sources often move between oral and injected use.", "proposed_rationale": "KPV is a short peptide derived from alpha-MSH. The audited guides simplify receptor explanations; transport and model-specific findings require closer reading.", "evidence": "PepT1-related cellular and mouse-colitis experiments provide preclinical evidence. The FDA assessment did not identify clinical human studies in its reviewed evidence.", "limits": "Animal colitis improvement does not establish human Crohn disease treatment, a safe injection schedule or clinical efficacy of a gut stack.", "product_question": "Preserve exact molecule and route. KPV, LL-37 and larazotide are distinct interventions, not synonyms.", "research_question": "What do users mean by “gut improvement,” and which validated symptom/function measures could a future protocol consistently capture?" }, "es": { "reported_practice": "KPV aparece en pautas de intestino, piel e inflamación, solo o con BPC-157 y LL-37. Las fuentes cambian con frecuencia entre uso oral e inyectado.", "proposed_rationale": "KPV es un péptido corto derivado de alfa-MSH. Las guías simplifican explicaciones de receptores; transporte y hallazgos específicos del modelo requieren revisión.", "evidence": "Experimentos celulares y de colitis murina relacionados con PepT1 aportan evidencia preclínica. La evaluación FDA no identificó estudios clínicos humanos en la evidencia revisada.", "limits": "Mejoría de colitis animal no establece tratamiento humano de Crohn, pauta de inyección segura ni eficacia de una combinación intestinal.", "product_question": "Conserva molécula y vía exactas. KPV, LL-37 y larazotida son intervenciones diferentes, no sinónimos.", "research_question": "¿Qué significa “mejoría intestinal” para quien la refiere y qué medidas validadas podrían recogerse consistentemente?" }, "pdf_claim_links": [ { "claim_id": "C026", "source_id": "V2", "pdf_pages": "40" }, { "claim_id": "C062", "source_id": "H", "pdf_pages": "70–72" } ] }, { "id": "CP-ll-37", "slug": "ll-37", "name": "LL-37", "category": "gut-immune", "claim_ids": [ "C027", "C063" ], "source_locators": "V2 LL-37 discussion; Handbook LL-37 discussion; matrix LL-37 records", "references": [ "R15", "R06" ], "review_status": "editorial_draft_scientific_review_pending", "last_editorial_audit": "2026-10-15", "en": { "reported_practice": "LL-37 is described for antimicrobial, biofilm and inflammatory aims, sometimes as a systemic component of a gut or immune combination.", "proposed_rationale": "Host-defense biology motivates the claim, but a molecule’s antimicrobial activity in an experiment does not establish safe systemic treatment.", "evidence": "A controlled topical leg-ulcer trial did not show overall benefit; exploratory findings in larger ulcers do not replace its main result.", "limits": "Topical research cannot establish injected antibiofilm efficacy. Site, concentration, formulation and exposure matter to both benefit and harm.", "product_question": "Is the cited study topical while the reported exposure is injected? Make the mismatch visible.", "research_question": "How frequently do community accounts preserve infection confirmation and the exact outcome, rather than infer “biofilm clearance” from nonspecific symptoms?" }, "es": { "reported_practice": "LL-37 se describe para objetivos antimicrobianos, biopelículas e inflamación, a veces como parte sistémica de una combinación intestinal o inmunitaria.", "proposed_rationale": "La biología de defensa del huésped motiva la afirmación, pero actividad experimental no establece un tratamiento sistémico seguro.", "evidence": "Un ensayo controlado tópico de úlceras de pierna no mostró beneficio global; los hallazgos exploratorios en úlceras grandes no sustituyen el resultado principal.", "limits": "La investigación tópica no establece eficacia inyectada contra biopelículas. Sitio, concentración, formulación y exposición importan para beneficio y daño.", "product_question": "¿El estudio citado es tópico mientras la exposición reportada es inyectada? Haz visible esa diferencia.", "research_question": "¿Los relatos conservan confirmación de infección y desenlace exacto o infieren eliminación de biopelículas por síntomas inespecíficos?" }, "pdf_claim_links": [ { "claim_id": "C027", "source_id": "V2", "pdf_pages": "41" }, { "claim_id": "C063", "source_id": "H", "pdf_pages": "73–83; especially 74–75" } ] }, { "id": "CP-thymosin-alpha-1", "slug": "thymosin-alpha-1", "name": "Thymosin α1 / Timosina α1", "category": "gut-immune", "claim_ids": [ "C070" ], "source_locators": "Handbook and Seeds immune discussions; matrix TA1 record", "references": [ "R16" ], "review_status": "editorial_draft_scientific_review_pending", "last_editorial_audit": "2026-10-15", "en": { "reported_practice": "Practitioner sources describe broad immune support and extrapolate between infections and other conditions.", "proposed_rationale": "Immune signaling is context dependent. “Boosting immunity” is too imprecise to describe a measurable clinical benefit.", "evidence": "The large TESTS sepsis trial did not demonstrate a mortality benefit. Its result and linked correction belong in any account of that indication.", "limits": "This is not a determination that every indication is ineffective or that all jurisdictions share an approval status. Each claim needs its own study and product context.", "product_question": "Which preparation, jurisdiction and indication are being described? Do not treat a broad class label as authorization.", "research_question": "Can future evidence mapping separate disease-specific outcomes from the nonspecific phrase “immune support”?" }, "es": { "reported_practice": "Fuentes profesionales describen apoyo inmunitario amplio y extrapolan entre infecciones y otras condiciones.", "proposed_rationale": "La señalización inmunitaria depende del contexto. “Reforzar defensas” es demasiado impreciso para definir beneficio clínico medible.", "evidence": "El ensayo grande TESTS en sepsis no demostró beneficio de mortalidad. Su resultado y corrección vinculada deben acompañar la discusión de esa indicación.", "limits": "No determina ineficacia en toda indicación ni un estado de aprobación común entre países. Cada afirmación necesita estudio y producto propios.", "product_question": "¿Qué preparado, jurisdicción e indicación se describen? Una etiqueta de clase no constituye autorización.", "research_question": "¿Puede el mapa separar desenlaces de enfermedad de la frase inespecífica “apoyo inmunitario”?" }, "pdf_claim_links": [ { "claim_id": "C070", "source_id": "H", "pdf_pages": "149–153; S 142–151, 61–68" } ] }, { "id": "CP-dsip", "slug": "dsip", "name": "DSIP", "category": "brain-sleep", "claim_ids": [ "C016" ], "source_locators": "V2 DSIP discussion; matrix C016", "references": [ "R18" ], "review_status": "editorial_draft_scientific_review_pending", "last_editorial_audit": "2026-10-15", "en": { "reported_practice": "DSIP is promoted for deep sleep and is paired with Epitalon in some accounts. Some schedules imply reliable or chronic benefit.", "proposed_rationale": "The name and proposed sleep biology do not demonstrate restoration of sleep architecture or superiority to other approaches.", "evidence": "A small double-blind insomnia study found limited selective effects rather than a major overall benefit.", "limits": "This evidence does not validate long-term combination cycles or a universal sleep-restoration claim. Subjective sleep and measured sleep outcomes should remain separate.", "product_question": "What material and route were used, and is the reported outcome a subjective impression or a comparable measurement?", "research_question": "Can independently occurring exposures be documented with consistent sleep measures, work schedules, caffeine, other medicines and missing follow-up?" }, "es": { "reported_practice": "DSIP se promociona para sueño profundo y se combina con Epitalon en algunos relatos. Ciertos calendarios sugieren beneficio fiable o crónico.", "proposed_rationale": "El nombre y la biología propuesta no demuestran restauración de arquitectura del sueño ni superioridad frente a otras opciones.", "evidence": "Un ensayo pequeño doble ciego en insomnio encontró efectos selectivos limitados, sin un beneficio global importante.", "limits": "No valida ciclos combinados prolongados ni una promesa universal de restauración del sueño. Deben separarse sueño subjetivo y desenlaces medidos.", "product_question": "¿Qué material y vía se usaron y el resultado es una impresión o una medida comparable?", "research_question": "¿Pueden documentarse sueño, horarios laborales, cafeína, medicamentos y pérdidas de seguimiento de manera consistente?" }, "pdf_claim_links": [ { "claim_id": "C016", "source_id": "V2", "pdf_pages": "26–29; V4 9–10" } ] }, { "id": "CP-semax-selank", "slug": "semax-selank", "name": "Semax / Selank", "category": "brain-sleep", "claim_ids": [ "C028", "C068" ], "source_locators": "V2 and Handbook neuropeptide discussions; matrix Semax/Selank records", "references": [ "R19", "R20" ], "review_status": "editorial_draft_scientific_review_pending", "last_editorial_audit": "2026-10-15", "en": { "reported_practice": "Semax and Selank are described for focus, anxiety, stress and cognitive performance. They are different molecules even when discussed together.", "proposed_rationale": "Neurobiological mechanisms and regional clinical reports are offered as explanations. A mechanism does not establish healthy-person cognitive enhancement.", "evidence": "The audit located limited, context-specific human and experimental evidence. Study quality, population and accessibility of full methods constrain broad conclusions.", "limits": "Do not describe all cognitive or anxiety uses as clinically established, or claim that nasal delivery makes safety questions disappear.", "product_question": "Which molecule, formulation, route, indication and jurisdiction are documented? Keep the records separate.", "research_question": "Can reports distinguish a defined symptom outcome from general productivity, expectancy effects and concurrent sleep or medication changes?" }, "es": { "reported_practice": "Semax y Selank se describen para atención, ansiedad, estrés y rendimiento cognitivo. Son moléculas distintas aunque se discutan juntas.", "proposed_rationale": "Mecanismos neurobiológicos e informes clínicos regionales se ofrecen como explicación. El mecanismo no establece mejora cognitiva en personas sanas.", "evidence": "La auditoría localizó evidencia humana y experimental limitada y específica del contexto. Calidad, población y acceso a métodos completos restringen conclusiones amplias.", "limits": "No presentes todos los usos cognitivos o de ansiedad como establecidos ni supongas que la vía nasal elimina preguntas de seguridad.", "product_question": "¿Qué molécula, formulación, vía, indicación y jurisdicción se documentan? Mantén registros separados.", "research_question": "¿Los relatos distinguen síntomas definidos de productividad general, expectativas y cambios simultáneos de sueño o medicación?" }, "pdf_claim_links": [ { "claim_id": "C028", "source_id": "V2", "pdf_pages": "42–43; V3 17, 24" }, { "claim_id": "C068", "source_id": "H", "pdf_pages": "120–127; S 187–193" } ] }, { "id": "CP-mots-c", "slug": "mots-c", "name": "MOTS-c", "category": "mitochondria", "claim_ids": [ "C018" ], "source_locators": "V2 PDF31; matrix C018", "references": [ "R21" ], "review_status": "editorial_draft_scientific_review_pending", "last_editorial_audit": "2026-10-15", "en": { "reported_practice": "MOTS-c is described in exercise, insulin-sensitivity and metabolic combinations. Community injection cycles extend beyond what an endogenous measurement can establish.", "proposed_rationale": "AMPK-related biology and mitochondrial signaling motivate interest. Endogenous associations and administering an external peptide are different interventions.", "evidence": "Important findings include experimental models and human exercise-related observations. These do not validate the book’s repeated injection cycle in healthy users.", "limits": "Do not infer improved performance, long-term metabolic benefit or longevity from a pathway diagram or circulating peptide association.", "product_question": "Is the material MOTS-c itself, a modified analogue, or an incompletely identified product? Those exposures cannot be pooled automatically.", "research_question": "Which outcomes are feasible to measure consistently without changing treatment or encouraging exposure for the sake of data?" }, "es": { "reported_practice": "MOTS-c se describe en ejercicio, sensibilidad a insulina y combinaciones metabólicas. Los ciclos de inyección exceden lo que demuestra una medición endógena.", "proposed_rationale": "La biología de AMPK y señalización mitocondrial motiva interés. Asociaciones endógenas y administrar un péptido externo son intervenciones diferentes.", "evidence": "Los hallazgos relevantes incluyen modelos experimentales y observaciones humanas relacionadas con ejercicio. No validan el ciclo repetido del libro en personas sanas.", "limits": "No infieras rendimiento, beneficio metabólico prolongado o longevidad por un diagrama de vías o una asociación circulante.", "product_question": "¿El material es MOTS-c, un análogo modificado o un producto de identidad incompleta? No deben agruparse automáticamente.", "research_question": "¿Qué desenlaces pueden medirse consistentemente sin cambiar tratamientos ni promover exposiciones para obtener datos?" }, "pdf_claim_links": [ { "claim_id": "C018", "source_id": "V2", "pdf_pages": "31; V4 29–30; 31" } ] }, { "id": "CP-elamipretide", "slug": "elamipretide", "name": "Elamipretide / SS-31", "category": "mitochondria", "claim_ids": [ "C019" ], "source_locators": "V2 mitochondrial discussion; matrix C019", "references": [ "R22", "R23" ], "review_status": "editorial_draft_scientific_review_pending", "last_editorial_audit": "2026-10-15", "en": { "reported_practice": "SS-31 is described for fatigue, athletic recovery and mitochondrial optimization, sometimes paired with metabolic compounds.", "proposed_rationale": "Mitochondrial membrane biology explains research interest. “Mitochondrial support” must be translated into a defined patient outcome.", "evidence": "Forzinity received a narrow US accelerated approval in 2025 for muscle strength in Barth syndrome in patients meeting the labeled weight threshold.", "limits": "The small study and approval conditions matter. This is not approval for general fatigue, anti-aging, athletic optimization or every research-grade SS-31 vial.", "product_question": "Is the discussion about the authorized product and labeled population, or a different preparation and intended use?", "research_question": "How frequently do community claims omit the rare-disease population and substitute a broad optimization claim?" }, "es": { "reported_practice": "SS-31 se describe para fatiga, recuperación deportiva y optimización mitocondrial, a veces con compuestos metabólicos.", "proposed_rationale": "La biología de membrana mitocondrial explica el interés. “Apoyo mitocondrial” debe traducirse en un desenlace definido.", "evidence": "Forzinity recibió en 2025 aprobación acelerada estadounidense acotada para fuerza muscular en síndrome de Barth, con el umbral de peso de su ficha.", "limits": "Importan el estudio pequeño y las condiciones de aprobación. No aprueba fatiga general, antienvejecimiento, optimización deportiva ni todo vial SS-31 de investigación.", "product_question": "¿Se discute el producto autorizado y su población o un preparado y uso diferentes?", "research_question": "¿Con qué frecuencia las afirmaciones omiten la población de enfermedad rara y la sustituyen por optimización general?" }, "pdf_claim_links": [ { "claim_id": "C019", "source_id": "V2", "pdf_pages": "32; V4 31–32" } ] }, { "id": "CP-epitalon", "slug": "epitalon", "name": "Epitalon", "category": "mitochondria", "claim_ids": [ "C017" ], "source_locators": "V2 Epitalon discussion; Seeds PDF111; matrix C017 and identity correction", "references": [ "R24" ], "review_status": "editorial_draft_scientific_review_pending", "last_editorial_audit": "2026-10-15", "en": { "reported_practice": "Epitalon appears in longevity and sleep-related cycles. Some accounts interpret telomerase or telomere findings as cellular rejuvenation.", "proposed_rationale": "Telomere biology motivates the hypothesis, but modifying a laboratory endpoint does not establish longer or healthier human life.", "evidence": "Cellular studies, including work involving normal and cancer-cell contexts, require model-specific interpretation. Cells of human origin do not make a study a clinical trial.", "limits": "No human lifespan benefit follows from these experiments. One source also misnames a residue; sequence identity must be checked before evidence is transferred.", "product_question": "Is the stated sequence AEDG and are modifications specified? A transcription error can change molecular identity.", "research_question": "Can an evidence map keep cellular endpoints, biomarker associations and patient outcomes in separate fields?" }, "es": { "reported_practice": "Epitalon aparece en ciclos de longevidad y sueño. Algunos relatos interpretan telomerasa o telómeros como rejuvenecimiento celular.", "proposed_rationale": "La biología telomérica motiva la hipótesis, pero modificar un desenlace de laboratorio no establece vida humana más larga o saludable.", "evidence": "Los estudios celulares, incluidos contextos de células normales y cancerosas, requieren interpretación específica. Células de origen humano no convierten un experimento en ensayo clínico.", "limits": "No se deduce beneficio de supervivencia humana. Una fuente nombra mal un residuo; debe comprobarse secuencia antes de transferir evidencia.", "product_question": "¿La secuencia declarada es AEDG y se especifican modificaciones? Un error de transcripción cambia identidad.", "research_question": "¿Puede el mapa conservar por separado desenlaces celulares, asociaciones de biomarcadores y resultados en pacientes?" }, "pdf_claim_links": [ { "claim_id": "C017", "source_id": "V2", "pdf_pages": "30" } ] }, { "id": "CP-humanin", "slug": "humanin", "name": "Humanin / Humanín", "category": "mitochondria", "claim_ids": [ "C020" ], "source_locators": "V2 Humanin discussion; matrix C020", "references": [ "R27" ], "review_status": "editorial_draft_scientific_review_pending", "last_editorial_audit": "2026-10-15", "en": { "reported_practice": "Humanin is described in anti-aging and mitochondrial combinations with repeated systemic dosing claims.", "proposed_rationale": "Cell-survival signaling and endogenous associations motivate research. These findings do not establish that external administration improves lifespan.", "evidence": "The audited mechanistic work is preclinical. Human associations, where discussed, are not trials of the guide’s injection regimen.", "limits": "The source’s dose summaries are internally inconsistent. Do not resolve the conflict by choosing the more familiar number or averaging the tables.", "product_question": "Confirm exact peptide or analogue and treat conflicting numeric claims as unresolved source issues.", "research_question": "Which claims derive from endogenous measurements versus actual administration, and can they be cataloged separately?" }, "es": { "reported_practice": "Humanín se describe en combinaciones antienvejecimiento y mitocondriales, con afirmaciones de administración sistémica repetida.", "proposed_rationale": "Señalización de supervivencia celular y asociaciones endógenas motivan investigación. No establecen que administrarlo prolongue la vida.", "evidence": "El trabajo mecanístico auditado es preclínico. Las asociaciones humanas mencionadas no son ensayos de la pauta inyectada de la guía.", "limits": "Los resúmenes de dosis de la fuente son internamente inconsistentes. No se resuelve el conflicto eligiendo una cifra familiar ni promediando tablas.", "product_question": "Confirma péptido o análogo exacto y conserva las cifras contradictorias como problema documental pendiente.", "research_question": "¿Qué afirmaciones provienen de mediciones endógenas y cuáles de administración real?" }, "pdf_claim_links": [ { "claim_id": "C020", "source_id": "V2", "pdf_pages": "33–34" } ] }, { "id": "CP-5-amino-1mq", "slug": "5-amino-1mq", "name": "5-amino-1MQ", "category": "metabolic", "claim_ids": [ "C021" ], "source_locators": "V2 and V4 5-amino-1MQ discussions; matrix C021", "references": [ "R26" ], "review_status": "editorial_draft_scientific_review_pending", "last_editorial_audit": "2026-10-15", "en": { "reported_practice": "5-amino-1MQ is included in peptide-oriented guides for fat loss and metabolic combinations, although it is a small molecule rather than a peptide.", "proposed_rationale": "NNMT inhibition is proposed to alter metabolism. NNMT methylates nicotinamide; shorthand suggesting direct NAD methylation is inaccurate.", "evidence": "The cited work includes mouse experiments. It does not establish the guide’s human dosing, cognitive benefits or longevity outcomes.", "limits": "Putting a compound in a peptide book does not change its chemical class or confer clinical evidence. Combination claims require their own evaluation.", "product_question": "Confirm the chemical identity and distinguish it from related inhibitors or similarly named research products.", "research_question": "How often do educational and commercial summaries misclassify the compound or extend animal endpoints into human claims?" }, "es": { "reported_practice": "5-amino-1MQ aparece en guías de péptidos para pérdida de grasa y combinaciones metabólicas, aunque es una molécula pequeña y no un péptido.", "proposed_rationale": "Se propone modificar metabolismo mediante inhibición de NNMT. NNMT metila nicotinamida; atribuirle metilación directa de NAD es inexacto.", "evidence": "El trabajo citado incluye experimentos en ratones. No establece dosis humana de la guía ni beneficios cognitivos o de longevidad.", "limits": "Incluirlo en un libro de péptidos no cambia su clase química ni aporta evidencia clínica. Las combinaciones requieren evaluación propia.", "product_question": "Confirma identidad química y distingue otros inhibidores o productos de nombre parecido.", "research_question": "¿Con qué frecuencia resúmenes educativos o comerciales clasifican mal el compuesto o convierten desenlaces animales en afirmaciones humanas?" }, "pdf_claim_links": [ { "claim_id": "C021", "source_id": "V2", "pdf_pages": "35; V4 33–34" } ] }, { "id": "CP-dihexa", "slug": "dihexa", "name": "Dihexa", "category": "brain-sleep", "claim_ids": [ "C059" ], "source_locators": "Handbook Dihexa section; matrix Dihexa retraction record", "references": [ "R37" ], "review_status": "editorial_draft_scientific_review_pending", "last_editorial_audit": "2026-10-15", "en": { "reported_practice": "Dihexa is described for cognitive enhancement using mechanistic arguments involving HGF/c-Met signaling.", "proposed_rationale": "The proposed mechanism attracted interest, but a plausible pathway depends on reliable supporting experiments.", "evidence": "A key 2014 mechanism paper was retracted in 2025. The retraction record must accompany any discussion relying on that work.", "limits": "Remove the paper as affirmative support and reassess dependent claims. Retraction does not establish that every possible claim about Dihexa is false.", "product_question": "An analytically identified material still cannot inherit efficacy from retracted evidence.", "research_question": "Which downstream reviews and community claims continued to cite the retracted paper without acknowledging its status?" }, "es": { "reported_practice": "Dihexa se describe para mejora cognitiva mediante argumentos de señalización HGF/c-Met.", "proposed_rationale": "El mecanismo propuesto generó interés, pero una vía plausible depende de experimentos fiables que la respalden.", "evidence": "Un artículo mecanístico clave de 2014 fue retractado en 2025. El registro de retractación debe acompañar toda discusión que dependa de él.", "limits": "Retira ese apoyo afirmativo y revisa las afirmaciones dependientes. La retractación no demuestra falsedad de toda afirmación posible sobre Dihexa.", "product_question": "Incluso un material identificado analíticamente no hereda eficacia de evidencia retractada.", "research_question": "¿Qué revisiones y afirmaciones comunitarias siguieron citando el artículo sin indicar su estado?" }, "pdf_claim_links": [ { "claim_id": "C059", "source_id": "H", "pdf_pages": "42–44; S 194–196; V2 51" } ] }, { "id": "CP-pnc-27", "slug": "pnc-27", "name": "PNC-27", "category": "emerging", "claim_ids": [ "C066" ], "source_locators": "Handbook PDF109; matrix PNC-27 and critical-unit-error records", "references": [ "R38", "R39" ], "review_status": "editorial_draft_scientific_review_pending", "last_editorial_audit": "2026-10-15", "en": { "reported_practice": "PNC-27 appears in practitioner cancer-treatment discussions, including claims of selective tumor effects and aggressive numerical protocols.", "proposed_rationale": "Cancer-cell membrane mechanisms are offered as the rationale. Selectivity in experimental systems is not demonstrated clinical cancer control.", "evidence": "The cited laboratory work is preclinical. The audit also verified apparent concentration/dose-unit problems on the handbook page.", "limits": "Do not reuse those numbers or present a community cancer protocol as validated treatment. The error cannot be repaired by guessing what the author intended.", "product_question": "Product quality testing cannot supply the missing clinical efficacy and safety evidence.", "research_question": "Which specific claims depend on cell experiments, and how are those experiments transformed into unsupported treatment promises?" }, "es": { "reported_practice": "PNC-27 aparece en discusiones profesionales de tratamiento del cáncer, con promesas de selectividad tumoral y protocolos numéricos intensivos.", "proposed_rationale": "Se ofrecen mecanismos de membrana en células cancerosas. Selectividad experimental no demuestra control clínico del cáncer.", "evidence": "El trabajo de laboratorio citado es preclínico. La auditoría verificó además aparentes problemas de unidades de concentración/dosis en el manual.", "limits": "No reutilices esas cifras ni presentes un protocolo comunitario oncológico como validado. No se corrige el error adivinando la intención del autor.", "product_question": "Los análisis de calidad no aportan la eficacia y seguridad clínicas faltantes.", "research_question": "¿Qué afirmaciones dependen de experimentos celulares y cómo se transforman en promesas terapéuticas sin respaldo?" }, "pdf_claim_links": [ { "claim_id": "C066", "source_id": "H", "pdf_pages": "109–112" } ] }, { "id": "CP-wolverine", "slug": "wolverine", "name": "Wolverine", "category": "stacks", "claim_ids": [ "C007" ], "source_locators": "V2 PDF13; existing Academy6.6; matrix C007", "references": [ "R01", "R03", "R08" ], "review_status": "editorial_draft_scientific_review_pending", "last_editorial_audit": "2026-10-15", "en": { "reported_practice": "Wolverine commonly refers in these sources to BPC-157 with TB-500-related material. Reported compositions and schedules differ and may involve separate vials.", "proposed_rationale": "The rationale pairs proposed repair-related mechanisms. Different mechanisms do not establish clinical synergy or chemical compatibility.", "evidence": "A retrospective knee report included BPC-157 alone or with TB4, but does not establish superiority of a standardized Wolverine product.", "limits": "TB4 identity in a study cannot be assumed to match a TB-500 label. A named combination is not a universal formulation or validated recovery schedule.", "product_question": "List each component, identity confidence and formulation. Distinguish coadministration from a fixed mixture.", "research_question": "Can future records separate each ingredient and concurrent rehabilitation while retaining functional outcomes and discontinuations?" }, "es": { "reported_practice": "Wolverine suele referirse en estas fuentes a BPC-157 con material relacionado con TB-500. Composiciones y calendarios difieren y pueden usar viales separados.", "proposed_rationale": "La lógica combina mecanismos propuestos de reparación. Mecanismos distintos no establecen sinergia clínica ni compatibilidad química.", "evidence": "Un informe retrospectivo de rodilla incluyó BPC-157 solo o con TB4, sin establecer superioridad de un producto Wolverine estandarizado.", "limits": "La identidad TB4 de un estudio no se presume en una etiqueta TB-500. Un nombre no es formulación universal ni calendario validado de recuperación.", "product_question": "Enumera componentes, confianza en identidad y formulación. Distingue coadministración de mezcla fija.", "research_question": "¿Pueden futuros registros separar ingredientes y rehabilitación, conservando función y suspensiones?" }, "pdf_claim_links": [ { "claim_id": "C007", "source_id": "V2", "pdf_pages": "11–13" } ] }, { "id": "CP-glow-klow", "slug": "glow-klow", "name": "Glow / KLOW", "category": "stacks", "claim_ids": [ "C007", "C013", "C026" ], "source_locators": "Academy6.6; V2 repair/skin/gut combinations; matrix C007 C013", "references": [ "R03", "R02", "R06" ], "review_status": "editorial_draft_scientific_review_pending", "last_editorial_audit": "2026-10-15", "en": { "reported_practice": "Glow and KLOW are names for reported multicomponent mixtures involving BPC-157, TB-500-related material, GHK-Cu and sometimes KPV. Names do not fix the composition.", "proposed_rationale": "Sources combine skin, repair and inflammation aims. The combined rationale is a hypothesis about the mixture, not evidence of a measured combined effect.", "evidence": "Evidence for ingredients is heterogeneous and does not automatically establish the exact mixture’s efficacy, stability or safety.", "limits": "Total mass per vial is not a per-application dose. In a fixed mixture, changing the withdrawn volume changes every component’s quantity together.", "product_question": "Are all component masses and identities declared, and are compatibility/stability claims supported for that exact formulation?", "research_question": "How often are fixed-mixture proportions documented well enough to interpret exposure, and which fields are most often missing?" }, "es": { "reported_practice": "Glow y KLOW nombran mezclas reportadas con BPC-157, material relacionado con TB-500, GHK-Cu y a veces KPV. El nombre no fija composición.", "proposed_rationale": "Las fuentes combinan objetivos de piel, reparación e inflamación. Esa lógica es una hipótesis de la mezcla, no prueba de efecto conjunto medido.", "evidence": "La evidencia de ingredientes es heterogénea y no establece automáticamente eficacia, estabilidad o seguridad de la mezcla exacta.", "limits": "Masa total del vial no equivale a dosis por aplicación. En una mezcla fija, cambiar volumen extraído cambia conjuntamente todos los componentes.", "product_question": "¿Se declaran masas e identidades y hay respaldo de compatibilidad/estabilidad de esa formulación?", "research_question": "¿Se documentan proporciones suficientes para interpretar exposición y qué campos faltan más?" }, "pdf_claim_links": [ { "claim_id": "C007", "source_id": "V2", "pdf_pages": "11–13" }, { "claim_id": "C013", "source_id": "V2", "pdf_pages": "22–23; V4 5–8" }, { "claim_id": "C026", "source_id": "V2", "pdf_pages": "40" } ] }, { "id": "CP-metabolic-stacks", "slug": "metabolic-stacks", "name": "Metabolic combinations / Combinaciones metabólicas", "category": "stacks", "claim_ids": [ "C029", "C030", "C037" ], "source_locators": "V2 PDF47,55; matrix metabolic combination records", "references": [ "R21", "R28", "R29", "R30" ], "review_status": "editorial_draft_scientific_review_pending", "last_editorial_audit": "2026-10-15", "en": { "reported_practice": "Guides propose adding GH-axis products, MOTS-c, AOD-9604 or SS-31 to incretin-based treatment for fat loss, muscle preservation or energy.", "proposed_rationale": "Complementary receptor or metabolic pathways are offered as a rationale. A multi-receptor drug is not the same intervention as several independently sourced compounds.", "evidence": "Controlled trials support specific incretin or investigational multi-agonist interventions. Retatrutide has phase 3 evidence, which does not validate these informal stacks.", "limits": "Do not rank combinations by isolated weight-loss percentages from different trials. Lean mass, muscle strength, fatigue and weight are different outcomes.", "product_question": "Identify every ingredient, approved versus investigational product context, concurrent medicines and formulation uncertainty.", "research_question": "Can routine-care observation capture function, nutrition, activity, symptoms and discontinuation without directing participants to add compounds?" }, "es": { "reported_practice": "Las guías proponen añadir productos del eje GH, MOTS-c, AOD-9604 o SS-31 a tratamientos incretínicos para grasa, músculo o energía.", "proposed_rationale": "Se propone complementariedad de receptores o vías. Un fármaco multirreceptor no es la misma intervención que varios compuestos de origen independiente.", "evidence": "Ensayos controlados respaldan intervenciones incretínicas o multiagonistas específicas. Retatrutida tiene evidencia fase3; no valida estas combinaciones informales.", "limits": "No clasifiques combinaciones por porcentajes aislados de ensayos diferentes. Masa magra, fuerza, fatiga y peso son desenlaces distintos.", "product_question": "Identifica ingredientes, contexto aprobado o investigacional, medicamentos concomitantes e incertidumbre de formulación.", "research_question": "¿Puede observarse función, nutrición, actividad, síntomas y suspensión sin dirigir a participantes a añadir compuestos?" }, "pdf_claim_links": [ { "claim_id": "C029", "source_id": "V2", "pdf_pages": "44–47, 59" }, { "claim_id": "C030", "source_id": "V2", "pdf_pages": "47; V4 35–36, 43" }, { "claim_id": "C037", "source_id": "V3", "pdf_pages": "18, 21–27" } ] } ], "references": { "R01": { "id": "R01", "title": "FDA: BPC-157 evaluation, July 2026", "url": "https://www.fda.gov/media/193343/download" }, "R02": { "id": "R02", "title": "FDA: KPV evaluation, July 2026", "url": "https://www.fda.gov/media/193346/download" }, "R03": { "id": "R03", "title": "FDA: TB-500 evaluation, July 2026", "url": "https://www.fda.gov/media/193349/download" }, "R04": { "id": "R04", "title": "FDA: AOD-9604 evaluation, December 2024", "url": "https://www.fda.gov/media/183584/download" }, "R06": { "id": "R06", "title": "FDA: current bulk-substance safety-risk page", "url": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks" }, "R07": { "id": "R07", "title": "Lee and Burgess: intravenous BPC-157 pilot, 2025", "url": "https://pubmed.ncbi.nlm.nih.gov/40131143/" }, "R08": { "id": "R08", "title": "Intra-articular BPC-157 for knee pain, 2021", "url": "https://pubmed.ncbi.nlm.nih.gov/34324435/" }, "R09": { "id": "R09", "title": "Chang et al.: BPC-157 tendon fibroblast experiments, 2011", "url": "https://pubmed.ncbi.nlm.nih.gov/21030672/" }, "R10": { "id": "R10", "title": "Teichman et al.: CJC-1295 human pharmacology, 2006", "url": "https://pubmed.ncbi.nlm.nih.gov/16352683/" }, "R11": { "id": "R11", "title": "CJC-1295 and preserved GH pulsatility, 2006", "url": "https://pubmed.ncbi.nlm.nih.gov/17018654/" }, "R12": { "id": "R12", "title": "Beck et al.: ipamorelin postoperative ileus trial, 2014", "url": "https://pubmed.ncbi.nlm.nih.gov/25331030/" }, "R13": { "id": "R13", "title": "EGRIFTA WR prescribing information, revised March 2025", "url": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75&type=display" }, "R14": { "id": "R14", "title": "Dalmasso et al.: PepT1-mediated KPV uptake, 2008", "url": "https://pubmed.ncbi.nlm.nih.gov/18061177/" }, "R15": { "id": "R15", "title": "HEAL LL-37 phase IIb trial, 2021", "url": "https://pubmed.ncbi.nlm.nih.gov/34687253/" }, "R16": { "id": "R16", "title": "Thymosin alpha-1 TESTS phase 3 trial, 2025", "url": "https://pubmed.ncbi.nlm.nih.gov/39814420/" }, "R18": { "id": "R18", "title": "Bes et al.: DSIP insomnia trial, 1992", "url": "https://pubmed.ncbi.nlm.nih.gov/1299794/" }, "R19": { "id": "R19", "title": "Semax during ischemic-stroke rehabilitation, 2018", "url": "https://pubmed.ncbi.nlm.nih.gov/29798983/" }, "R20": { "id": "R20", "title": "Zozulia et al.: Selank versus medazepam, 2008", "url": "https://pubmed.ncbi.nlm.nih.gov/18454096/" }, "R21": { "id": "R21", "title": "Reynolds et al.: MOTS-c and exercise, 2021", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7817689/" }, "R22": { "id": "R22", "title": "FDA: Forzinity drug-trial snapshot", "url": "https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-forzinity" }, "R23": { "id": "R23", "title": "Forzinity prescribing information, 2025", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/215244Orig1s000Lbl.pdf" }, "R24": { "id": "R24", "title": "Al-Dulaimi et al.: Epitalon in cell lines, 2025", "url": "https://pubmed.ncbi.nlm.nih.gov/40908429/" }, "R26": { "id": "R26", "title": "Neelakantan et al.: NNMT inhibitors in obese mice, 2018", "url": "https://pubmed.ncbi.nlm.nih.gov/29155147/" }, "R27": { "id": "R27", "title": "Guo et al.: Humanin and BAX, 2003", "url": "https://pubmed.ncbi.nlm.nih.gov/12732850/" }, "R28": { "id": "R28", "title": "Retatrutide obesity phase 2 trial, 2023", "url": "https://pubmed.ncbi.nlm.nih.gov/37366315/" }, "R29": { "id": "R29", "title": "TRIUMPH-2 retatrutide phase 3 publication, 2026", "url": "https://pubmed.ncbi.nlm.nih.gov/42810372/" }, "R30": { "id": "R30", "title": "FDA: concerns with unapproved GLP-1 drugs", "url": "https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss" }, "R31": { "id": "R31", "title": "Vyleesi prescribing information", "url": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf&type=display" }, "R32": { "id": "R32", "title": "FDA: Scenesse approved indication", "url": "https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=263208" }, "R33": { "id": "R33", "title": "TGA: melanotan tanning warning, 2025", "url": "https://www.tga.gov.au/news/blog/dont-risk-using-tanning-products-containing-melanotan" }, "R34": { "id": "R34", "title": "TGA: Melanotan II laboratory testing, August 2026", "url": "https://www.tga.gov.au/safety/safety-monitoring-and-information/safety-alerts/melanotan-ii-tanning-peptide-products-found-be-inconsistently-dosed" }, "R35": { "id": "R35", "title": "Sosne and Ousler: thymosin beta-4 dry-eye trial, 2015", "url": "https://pubmed.ncbi.nlm.nih.gov/26056426/" }, "R37": { "id": "R37", "title": "Dihexa mechanism paper: retraction record, 2025", "url": "https://pubmed.ncbi.nlm.nih.gov/40312093/" }, "R38": { "id": "R38", "title": "PNC-27 HDM-2 cell study, 2010", "url": "https://pubmed.ncbi.nlm.nih.gov/20080680/" }, "R39": { "id": "R39", "title": "FDA: illegal cancer products and PNC-27 contamination", "url": "https://www.fda.gov/consumers/health-fraud-scams/questions-and-answers-fda-alerts-companies-stop-illegal-sale-products-claiming-treat-cancer" } }, "review_status": "DRAFT_EDITORIAL_SCIENTIFIC_TRANSLATION_REVIEW_PENDING", "license": "No open-data license has been designated; do not imply a license for the source books.", "reported_quantity_examples": [ { "profile_slug": "bpc-157", "source_id": "V2", "pdf_page": 13, "claim_id": "C006", "en": { "reported_quantity": "500 micrograms/day in an early injury phase; the same source later describes 250 micrograms/day.", "interpretation": "These are author-reported quantities, not a clinical comparison or a course-recommended range. The source also changes other interventions across phases." }, "es": { "reported_quantity": "500 microgramos/día en una fase inicial de lesión; la misma fuente describe después 250 microgramos/día.", "interpretation": "Son cantidades reportadas por el autor, no una comparación clínica ni un rango recomendado. La fuente también cambia otras intervenciones entre fases." }, "references": [ "R01", "R08" ] }, { "profile_slug": "mots-c", "source_id": "V2", "pdf_page": 31, "claim_id": "C018", "en": { "reported_quantity": "The source labels 5 mg as a minimum dose.", "interpretation": "A label in a practitioner guide does not establish a validated human minimum, safe dose or effective regimen. Experimental and endogenous evidence cannot supply that validation." }, "es": { "reported_quantity": "La fuente rotula 5 mg como dosis mínima.", "interpretation": "Una etiqueta en una guía no establece mínimo humano validado, dosis segura ni pauta eficaz. La evidencia experimental y endógena no aporta esa validación." }, "references": [ "R21" ] }, { "profile_slug": "kpv", "source_id": "V2", "pdf_page": 40, "claim_id": "C026", "en": { "reported_quantity": "The source gives 150–750 micrograms/day while discussing oral or subcutaneous use.", "interpretation": "Combining routes in a source table does not establish equivalence. The audited preclinical evidence and FDA review do not validate that human schedule." }, "es": { "reported_quantity": "La fuente da 150–750 microgramos/día al discutir uso oral o subcutáneo.", "interpretation": "Agrupar vías en una tabla no establece equivalencia. La evidencia preclínica auditada y revisión FDA no validan ese calendario humano." }, "references": [ "R02", "R14" ] } ] }